Ene I Ette

age ~70

from Framingham, MA

Get Report
Also known as:
  • Ene Dr Ette
  • Ene Esther Ette
  • Ene O Ette
  • Nkaepe Ette
  • Ikpong Ette Ene
  • Ette Ene
Phone and address:
8 Summer Ln, Framingham, MA 01701
5083159927
Connected to:

Ene Ette Phones & Addresses

  • 8 Summer Ln, Framingham, MA 01701 • 5083159927
  • Natick, MA
  • 12903 Crookston Ln, Rockville, MD 20851
  • Houston, TX
  • Essex, MD

Work

  • Company:
    Anoixis corporation
    Oct 2006
  • Address:
    Natick, MA
  • Position:
    President & ceo

Education

  • Degree:
    Ph.D. (Clinical Pharmacology
  • School / High School:
    The University of Glasgow
    1988 to 1991
  • Specialities:
    Pharmacometrics

Skills

Drug Development • Clinical Pharmacology • Pharmacokinetics • Clinical Development • Pharmacometrics • Pharmacodynamics • Fda • Pharmaceutical Industry • Pharmacology • Clinical Trials • Gcp • Drug Discovery • Pk/Pd • Biomarkers • Drug Delivery • Cro • Regulatory Submissions • Infectious Diseases • Oncology • Biopharmaceuticals • Medical Writing • Modeling and Simulation • Population Pk/Pd Modeling • Ind • Good Clinical Practice • U.s. Food and Drug Administration • Winnonlin • Cancer • Toxicology • Translational Medicine • Cro Management • Population Pk • Exposure Response Analysis • Clinical Study Design • Strategic Consulting • Translational Research • Exposure Qtc Analysis • Scenario Planning • Drug Development Strategy • Ectd Clinical Pharmacology Sections

Industries

Pharmaceuticals

Resumes

Ene Ette Photo 1

President And Chief Executive Officer

view source
Location:
214 north Main St, Natick, MA 01760
Industry:
Pharmaceuticals
Work:
Anoixis Corporation - Natick, MA since Oct 2006
President & CEO
Vertex Pharmaceuticals Aug 1997 - Oct 2006
Sr. Director /Global Head, Dept. of Clinical Pharmacology
U.S. Food and Drug Administration - Rockville, MD Jun 1992 - Aug 1997
Senior Reviewer/Expert Scientist (Pharmacometrics)
Education:
The University of Glasgow 1988 - 1991
Ph.D. (Clinical Pharmacology, Pharmacometrics
Skills:
Drug Development
Clinical Pharmacology
Pharmacokinetics
Clinical Development
Pharmacometrics
Pharmacodynamics
Fda
Pharmaceutical Industry
Pharmacology
Clinical Trials
Gcp
Drug Discovery
Pk/Pd
Biomarkers
Drug Delivery
Cro
Regulatory Submissions
Infectious Diseases
Oncology
Biopharmaceuticals
Medical Writing
Modeling and Simulation
Population Pk/Pd Modeling
Ind
Good Clinical Practice
U.s. Food and Drug Administration
Winnonlin
Cancer
Toxicology
Translational Medicine
Cro Management
Population Pk
Exposure Response Analysis
Clinical Study Design
Strategic Consulting
Translational Research
Exposure Qtc Analysis
Scenario Planning
Drug Development Strategy
Ectd Clinical Pharmacology Sections

Isbn (Books And Publications)

Pharmacometrics: The Science of Quantitative Pharmacology

view source

Author
Ene I. Ette

ISBN #
0471677833

Us Patents

  • Compositions Comprising Impdh Inhibitors And Uses Thereof For Treating Hcv Infection

    view source
  • US Patent:
    7371372, May 13, 2008
  • Filed:
    Sep 28, 2004
  • Appl. No.:
    10/951382
  • Inventors:
    Pravin Chaturvedi - Andover MA, US
    Ene Ette - Framingham MA, US
  • Assignee:
    Vertex Pharmaceuticals Incorporated - Cambridge MA
  • International Classification:
    A61K 38/21
    A61K 38/00
  • US Classification:
    424 857, 424 854, 514 2, 514588, 514894
  • Abstract:
    The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or pegylated alpha-interferon and an IMPDH inhibitor selected from VX-148 or VX-944, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein:The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.

  • Dose Forms

    view source
  • US Patent:
    8431615, Apr 30, 2013
  • Filed:
    Oct 31, 2005
  • Appl. No.:
    11/264746
  • Inventors:
    Hui-May Chu - Natick MA, US
    Ene Ette - Framingham MA, US
    Lindsay McNair - Allston MA, US
    John Alam - Cambridge MA, US
  • Assignee:
    Vertex Pharmaceuticals Incorporated - Cambridge MA
  • International Classification:
    A61K 38/21
    A61K 38/00
    A61K 31/14
  • US Classification:
    514588, 514 43, 514894, 424 857, 424 854
  • Abstract:
    The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.

  • Optimal Compositions And Methods Thereof For Treating Hcv Infections

    view source
  • US Patent:
    20030068302, Apr 10, 2003
  • Filed:
    Aug 28, 2001
  • Appl. No.:
    09/941282
  • Inventors:
    Pravin Chaturvedi - Andover MA, US
    Ene Ette - Framingham MA, US
  • International Classification:
    A61K038/21
    A61K031/7056
    A61K031/365
  • US Classification:
    424/085700, 514/043000, 514/470000
  • Abstract:
    The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or a derivative thereof and an IMPDH inhibitor, wherein the IMPDH inhibitor is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10, wherein: a Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and a Cmin is estimated trough concentration produced by said IMPDH inhibitor in said human. The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.

  • Methods For Determining Optimal Doses For A First Investigational Administration In Humans

    view source
  • US Patent:
    20050015225, Jan 20, 2005
  • Filed:
    May 6, 2004
  • Appl. No.:
    10/840197
  • Inventors:
    Christopher Godfrey - Natick MA, US
    Amit Roy - Plainsboro NJ, US
    Ene Ette - Framingham MA, US
  • International Classification:
    G06F017/10
  • US Classification:
    703002000
  • Abstract:
    The present invention provides a method for determining an optimal dose range of a compound for a first investigational administration of that compound in a human. The method involves stochastic simulation of allometric parameters to produce outcome distributions that provide a basis for selecting an optimal dose range. The present invention also provides optimal doses of compounds under clinical evaluation in the first administration of such compounds to humans.

  • Combination Therapy For Hcv Infection

    view source
  • US Patent:
    20050112093, May 26, 2005
  • Filed:
    Oct 12, 2004
  • Appl. No.:
    10/964243
  • Inventors:
    Ene Ette - Framingham MA, US
    John Alam - Cambridge MA, US
    Robert Kauffman - Chestnut Hill MA, US
  • International Classification:
    A61K038/21
    A61K038/05
    A61K031/7056
  • US Classification:
    424085400, 514043000, 514018000
  • Abstract:
    The present invention relates to therapeutic combinations comprising VX-497, ribavirin, and interferon. The present invention also relates to methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.

  • Compositions And Methods For Treating Anemia

    view source
  • US Patent:
    20230071553, Mar 9, 2023
  • Filed:
    Apr 4, 2022
  • Appl. No.:
    17/712709
  • Inventors:
    - Cambridge MA, US
    Gurudatt Ajay Chandorkar - Waltham MA, US
    Ene Ikpong Ette - Framingham MA, US
    Bradley John Maroni - Boston MA, US
    Charlotte Suzanne Hartman - Carmel IN, US
    Ramin Farzaneh-Far - Brookline MA, US
    Jula Kern Inrig - Yorba Linda CA, US
  • International Classification:
    A61K 31/4418
    A61K 9/20
    A61K 9/28
    A61K 31/16
    C07D 213/81
  • Abstract:
    Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

  • Compositions And Methods For Treating Anemia

    view source
  • US Patent:
    20180092892, Apr 5, 2018
  • Filed:
    Mar 31, 2016
  • Appl. No.:
    15/563169
  • Inventors:
    - Cambridge MA, US
    Gurudatt Ajay Chandorkar - Waltham MA, US
    Ene Ikpong Ette - Framingham MA, US
    Bradley John Maroni - Boston MA, US
    Charlotte Suzanne Hartman - Carmel IN, US
    Ramin Farzaneh-Far - Brookline MA, US
    Jula Kem Inrig - Yorba Linda CA, US
  • Assignee:
    Akebia Therapeutics, Inc. - Cambridge MA
  • International Classification:
    A61K 31/4418
    A61K 9/20
    A61K 9/28
  • Abstract:
    Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Name / Title
Company / Classification
Phones & Addresses
Ene I Ette
President
ALAYTHACE PUBLISHING CORPORATION
214 N Main St SUITE 104, Natick, MA 01760
8 Summer Ln, Framingham, MA 01701
Ene I Ette
Manager
PERISSEU, LLC
214 N Main St STE 104, Natick, MA 01760
Ene I Ette
President, Chief Executive Officer/president
Anoixis Corporation
Pharmaceuticals · Whol Drugs/Sundries
214 N Main St SUITE 104, Natick, MA 01760
8 Summer Ln, Framingham, MA 01701
5086479470
Get Report for Ene I Ette from Framingham, MA, age ~70
Control profile